Ouro launches with $115M and a clinical-stage T-cell engager
22 hours ago · GSK-backed Ouro Medicines launches into T-cell engager space with $120M and a clinical-stage asset. By Darren Incorvaia Jan 10, 2025 6:00am. GSK bispecific antibodies B cells autoimmune ...
GSK-backed Ouro Launches With $115M to ‘Reset’ the Immune …
22 hours ago · Ouro is planning to leverage T cell engagers to deplete B cells and “reset” the immune system to treat immune-mediated diseases. ... GSK-backed Ouro Launches With $115M to ‘Reset’ the Immune System. January 10, 2025 | 2 min read | Tristan Manalac. ... BioSpace is the digital hub for life science news and jobs. We provide essential ...
Ouro Medicines Launches to Define the Future of Treatment for …
22 hours ago · News provided by Ouro Medicines Jan 10, 2025, 06:00 ET. Share this article. Share ... Ouro was founded by Monograph Capital in partnership with GSK. Ouro is also backed by leading investors TPG ...
Ouro Medicines Launches to Define the Future of Treatment for …
1 day ago · Company founded by Monograph Capital in partnership with GSK; Series A co-led by TPG, NEA, and Norwest. San Francisco, January 10, 2025-- Ouro Medicines, a biotechnology company developing immune reset therapeutics for people living with chronic immune-mediated diseases, today announced its launch with $120 million in funding. The company was ...
Ouro makes debut with $120m for autoimmune disease TCEs
20 hours ago · Ouro launches today with $120m in funding and a plan to develop bispecific antibody-based T-cell engagers for autoimmune ... Founded by Monograph Capital and GSK, the San Francisco–based company ...
Immunology Startup Ouro Sets Out With $120M for Drugs That …
1 day ago · Ouro’s Series A round was co-led by TPG Life Sciences Innovations, NEA, and Norwest Venture Partners. Other disclosed investors in the financing include Monograph Capital, GSK, Boyu/Zoo Capital ...
Ouro Medicines Launches to Define the Future of Treatment
22 hours ago · Based in San Francisco and launched in 2025, Ouro was founded by Monograph Capital in partnership with GSK. Ouro is also backed by leading investors TPG, NEA, and Norwest.
Ouro, backed by GSK, joins hunt to bring bispecifics to …
1 day ago · Ouro, backed by GSK, joins hunt to bring bispecifics to autoimmune disease “Practice of medicine could fundamentally change with these types of therapies,” said CEO Jaideep Dudani, whose startup raised $120 million in Series A funding. ... Subscribe to BioPharma Dive for top news, trends & analysis. Email: Select Newsletter: Daily Dive M-F;
Ouro Medicines Launches To Define The Future Of Treatment For …
1 day ago · Company founded by Monograph Capital in partnership with GSK; Series A co-led by TPG, NEA, and Norwest SAN FRANCISCO, Jan. 10, 2025 /PRNewswire/ -- Ouro Medicines, a biotechnology company ...
TPG : Ouro Medicines Launches to Define the Future of Treatment …
19 hours ago · Ouro's approach is focused on leveraging T cell engagers in B cell mediated diseases to achieve immune resets that create durable remissions without ongoing immunosuppression. Based in San Francisco and launched in 2025, Ouro was founded by Monograph Capital in partnership with GSK. Ouro is also …
- Some results have been removed